AGEN
Agenus Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.26
+0.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 132.7M | 114.2M | 103.5M | 156.3M | 98.0M |
| Cost of Revenue | 32.3M | 80.4M | 156.0M | 237.7M | 197.3M |
| Gross Profit | 100.4M | 33.8M | (52.6M) | (81.4M) | (99.2M) |
| Operating Expenses | |||||
| R&D Expense | 26.6M | — | 155.5M | 234.6M | — |
| SG&A Expense | 38.5M | 54.4M | 71.9M | 78.7M | 81.0M |
| General & Admin Expense | 38.5M | 54.4M | 71.9M | 78.7M | 81.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (901.0K) | — | (159.5M) | (235.1M) | (815.0K) |
| Total Operating Expenses | 64.2M | 54.4M | 67.9M | 78.2M | 80.2M |
| Cost and Expenses | 96.5M | 134.8M | 223.9M | 315.9M | 277.5M |
| Operating Income (EBIT) | 36.2M | (20.6M) | (120.5M) | (159.5M) | (179.4M) |
| Non-Operating | |||||
| Interest Income | 21.0K | — | — | — | — |
| Interest Expense | 59.1M | 55.3M | 117.6M | 97.9M | 61.9M |
| Net Interest Income | (59.1M) | (55.3M) | (117.6M) | (97.9M) | (61.9M) |
| Other Non-Op Income/Expense | 55.7M | 17.5M | (111.8M) | (97.9M) | (51.2M) |
| Non-Operating Income (excl Interest) | (114.9M) | (72.7M) | (5.8M) | (37.0K) | (10.6M) |
| EBT (Pre-Tax Income) | 91.9M | (3.1M) | (232.3M) | (257.4M) | (230.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | 92.0M | 115.0K | (227.2M) | (245.8M) | (220.1M) |
| Earnings from Cont. Ops | 91.9M | (3.1M) | (232.3M) | (257.4M) | (230.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 91.8M | (101.0K) | (227.4M) | (246.0M) | (220.3M) |
| Per Share | |||||
| Basic EPS | $2.72 | ($0.00) | ($10.59) | ($13.75) | ($15.64) |
| Diluted EPS | $2.65 | ($0.00) | ($10.59) | ($13.75) | ($15.64) |
| Revenue Per Share | $3.21 | $3.84 | $4.82 | $8.74 | $6.96 |
| Shares | |||||
| Basic Shares Outstanding | 41.3M | 29.7M | 21.5M | 17.9M | 14.1M |
| Diluted Shares Outstanding | 41.3M | 29.7M | 21.5M | 17.9M | 14.1M |
| Profitability Metrics | |||||
| EBITDA | 155.8M | 62.2M | (101.3M) | (145.9M) | (161.8M) |
| D&A | 4.7M | 10.0M | 13.3M | 13.6M | 6.9M |
| EBIT | 151.1M | 52.2M | (114.6M) | (159.5M) | (168.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026